Patent classifications
C12N2710/16152
HCMV vaccine strain
The present invention relates to nucleic acid molecules encoding a recombinant human cytomegalovirus (HCMV) strain, dense bodies produced by said HCMV strain and preparations of said dense bodies for use in medicine, particularly as a vaccine against HCMV.
MODIFIED CYTOMEGALOVIRUS PROTEINS AND STABILIZED COMPLEXES
Described are mutant, human cytomegalovirus (HCMV) pentamer complex polypeptides, methods of making them, and their use in HCMV protein complexes and compositions. In particular, the use of the modified HCMV polypeptides to stabilize HCMV complexes or unmask a pentamer epitope is described.
HCMV VACCINE STRAIN
The present invention relates to nucleic acid molecules encoding a recombinant human cytomegalovirus (HCMV) strain, dense bodies produced by said HCMV strain and preparations of said dense bodies for use in medicine, particularly as a vaccine against HCMV.
VACCINE AGAINST BETA-HERPESVIRUS INFECTION AND USE THEREOF
The present invention is related to a beta-herpesvirus, wherein the beta-herpesvirus is spread-deficient.
MODIFIED CYTOMEGALOVIRUS PROTEINS AND STABILIZED COMPLEXES
Described are mutant, human cytomegalovirus (HCMV) pentamer complex polypeptides, methods of making them, and their use in HCMV protein complexes and compositions. In particular, the use of the modified HCMV polypeptides to stabilize HCMV complexes or unmask a pentamer epitope is described.
METHODS FOR PRODUCING CMV VECTORS
The present disclosure provides methods for producing cytomegalovirus (CMV) viral vectors. The present disclosure also provides methods for modifying host cells for use in producing CMV viral vectors.